The use of interleukin (IL)-23 inhibitors plays an important role in treating patients with psoriasis, as well as in treating ...

Beijing Innocare Pharma Tech Co. Ltd. and Innocare Pharma Ltd. have identified compounds acting as interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction, interleukin-17A/A (IL17A/A) ...

The hidradenitis suppurativa market is poised for strong growth, driven by increasing disease awareness, earlier diagnosis, and expanding treatment access. Advances in biologic and targeted therapies, ...

A Danish registry study finds no substantial differences in the 5-year risk for first cancers between three biologics in patients with psoriasis.

A young woman shares her emotional 15-year journey with hidradenitis suppurativa, chronic skin inflammation for which ...

The "atopic march" describes the age-related progression of allergic diseases, presenting as the sequential onset of atopic ...

New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the ...

Guselkumab offers the flexibility of self-administration from the start of treatment in both ulcerative colitis (UC) and Crohn’s disease (CD),1,2,3 providing the simplicity of a fully subcutaneous ...

This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often ...

UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with active ...

IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan. LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinica ...

Background Lupus nephritis (LN) is the most serious complication of SLE. Interstitial fibrosis is the dominant pathological ...